Related Experiment Video
Updated: Jun 8, 2026
05:54
Operation Procedure and Precautions of Thread-Embedding Acupuncture Therapy in Alzheimer
Published on: May 10, 2024
Estrogen therapy and Alzheimer's dementia
Michael C Craig1, D G M Murphy
1Centre for Female Health and Neurodevelopment, Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Kings College London, London, United Kingdom. michael.c.craig@kcl.ac.uk
Annals of the New York Academy of Sciences
|September 16, 2010
Summary
Estrogen treatment (ET) may reduce Alzheimer's disease (AD) risk in postmenopausal women, especially when initiated around menopause. Starting ET later may offer neutral or negative effects on AD risk.
Area of Science:
- Neuroscience
- Endocrinology
- Gerontology
Background:
- Estrogen treatment (ET) has been linked to modulating Alzheimer's disease (AD) risk in postmenopausal women.
- A "critical period" hypothesis suggests ET initiated around menopause may offer neuroprotective benefits against AD.
- The timing of ET initiation may significantly influence its impact on AD risk.
Purpose of the Study:
- To review neurobiological mechanisms of estrogen's effects on the postmenopausal brain.
- To evaluate the "critical period" hypothesis for estrogen therapy and Alzheimer's disease risk reduction.
Main Methods:
- Review of recent in vivo studies analyzing neurobiological mechanisms.
- Synthesis of findings related to estrogen's impact on the brain in postmenopausal women.
Main Results:
- Estrogen's positive effects on the brain appear most robust when initiated around menopause.
- Initiating ET before age 49 may be most beneficial for reducing later-life AD risk.
- Late initiation of ET (after 60-65 years) may have neutral or negative effects on AD risk.
Conclusions:
- The timing of estrogen treatment initiation is critical for its potential neuroprotective effects against Alzheimer's disease.
- Estrogen therapy may be most effective for Alzheimer's disease prevention when started during the menopausal transition.
- Further research into neurobiological mechanisms can clarify optimal estrogen therapy strategies for cognitive health.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.